Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOAd703 in pancreatic cancer
NCT02705196Phase 2Completed
- Sponsor
- Lokon Pharma
- Start
- Nov 2016
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of delolimogene mupadenorepvec in pancreatic ductal adenocarcinoma (PDAC), sponsored by Lokon Pharma. Started Nov 2016; status: completed.
02
Drugs
delolimogene mupadenorepvec
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02705196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705196.